Abortion medication decisions from the Food and Drug Administration are facing another challenge, with several conservative states suing the agency and also asking to join an ongoing lawsuit that could determine the future of the drug’s accessibility.
Missouri, Idaho, and Kansas are urging the US District Court for the Northern District of Texas to issue a preliminary injunction that would rescind the FDA’s 2019 approval of a generic version of the abortion medication mifepristone and restore a requirement for the drug to be dispensed in person.
“Unelected federal bureaucrats do not have the statutory authority to approve the shipment of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.